High Court Agrees To Hear Pharma Entities’ ‘Skinny Label Infringement’ Fight
WASHINGTON, D.C. — The U.S. Supreme Court on Jan. 16 granted a bioequivalent pharmaceutical maker’s petition for a writ of certiorari, agreeing to consider its challenge to the Federal Circuit U.S....To view the full article, register now.
Already a subscriber? Click here to view full article